Movatterモバイル変換


[0]ホーム

URL:


US20030097152A1 - Method and apparatus for destroying dividing cells - Google Patents

Method and apparatus for destroying dividing cells
Download PDF

Info

Publication number
US20030097152A1
US20030097152A1US10/288,562US28856202AUS2003097152A1US 20030097152 A1US20030097152 A1US 20030097152A1US 28856202 AUS28856202 AUS 28856202AUS 2003097152 A1US2003097152 A1US 2003097152A1
Authority
US
United States
Prior art keywords
electric field
dividing cells
cells
cell
living tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US10/288,562
Other versions
US7016725B2 (en
Inventor
Yoram Palti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novocure GmbH
Bpcr LP
Original Assignee
Standen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10/288,562priorityCriticalpatent/US7016725B2/en
Application filed by Standen LtdfiledCriticalStanden Ltd
Assigned to STANDEN LTD.reassignmentSTANDEN LTD.ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: PALTI, YORAM
Publication of US20030097152A1publicationCriticalpatent/US20030097152A1/en
Priority to US11/111,393prioritypatent/US7599745B2/en
Priority to US11/111,236prioritypatent/US7805201B2/en
Priority to US11/111,439prioritypatent/US7565205B2/en
Priority to US11/318,702prioritypatent/US7565206B2/en
Application grantedgrantedCritical
Publication of US7016725B2publicationCriticalpatent/US7016725B2/en
Priority to US11/422,641prioritypatent/US7599746B2/en
Priority to US12/146,918prioritypatent/US8175698B2/en
Priority to US12/190,886prioritypatent/US7890183B2/en
Priority to US12/958,623prioritypatent/US8447395B2/en
Assigned to NOVOCURE LIMITEDreassignmentNOVOCURE LIMITEDCHANGE OF NAME (SEE DOCUMENT FOR DETAILS).Assignors: STANDEN LIMITED
Priority to US13/428,887prioritypatent/US8447396B2/en
Assigned to DEUTSCHE BANK TRUST COMPANY AMERICASreassignmentDEUTSCHE BANK TRUST COMPANY AMERICASSECURITY AGREEMENTAssignors: NOVOCURE LIMITED
Priority to US13/782,579prioritypatent/US9056203B2/en
Priority to US13/782,418prioritypatent/US9039674B2/en
Assigned to NOVOCURE LIMITEDreassignmentNOVOCURE LIMITEDRELEASE OF SECURITY INTERESTAssignors: DEUTSCHE BANK TRUST COMPANY AMERICAS
Assigned to BIOPHARMA SECURED INVESTMENTS III HOLDINGS CAYMAN LPreassignmentBIOPHARMA SECURED INVESTMENTS III HOLDINGS CAYMAN LPSECURITY INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: NOVOCURE LIMITED
Priority to US14/731,903prioritypatent/US9440068B2/en
Priority to US15/231,734prioritypatent/US9750934B2/en
Assigned to NOVOCURE LIMITEDreassignmentNOVOCURE LIMITEDRELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS).Assignors: BIOPHARMA SECURED INVESTMENTS III HOLDINGS CAYMAN LP
Assigned to BIOPHARMA CREDIT PLCreassignmentBIOPHARMA CREDIT PLCSECURITY INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: NOVOCURE LIMITED
Assigned to BIOPHARMA CREDIT PLCreassignmentBIOPHARMA CREDIT PLCSECURITY INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: NOVOCURE LIMITED
Assigned to BIOPHARMA CREDIT PLCreassignmentBIOPHARMA CREDIT PLCSECURITY INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: NOVOCURE GMBH
Assigned to NOVOCURE GMBHreassignmentNOVOCURE GMBHASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: NOVOCURE LIMITED
Assigned to NOVOCURE LIMITEDreassignmentNOVOCURE LIMITEDRELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS).Assignors: BIOPHARMA CREDIT PLC
Assigned to NOVOCURE LIMITEDreassignmentNOVOCURE LIMITEDRELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 045278/0825Assignors: BIOPHARMA CREDIT PLC
Assigned to BPCR LIMITED PARTNERSHIPreassignmentBPCR LIMITED PARTNERSHIPOMNIBUS CONFIRMATION OF ASSIGNMENT AGREEMENTAssignors: BIOPHARMA CREDIT PLC
Assigned to NOVOCURE GMBHreassignmentNOVOCURE GMBHRELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 50395/0398Assignors: BPCR LIMITED PARTNERSHIP
Assigned to NOVOCURE LIMITEDreassignmentNOVOCURE LIMITEDRELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 45278 0825Assignors: BIOPHARMA CREDIT PLC
Assigned to JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENTreassignmentJPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENTSECURITY INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: NOVOCURE GMBH
Assigned to NOVOCURE GMBHreassignmentNOVOCURE GMBHRELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS).Assignors: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Assigned to BIOPHARMA CREDIT PLCreassignmentBIOPHARMA CREDIT PLCPATENT SECURITY AGREEMENTAssignors: NOVOCURE GMBH (SWITZERLAND)
Adjusted expirationlegal-statusCritical
Expired - Lifetimelegal-statusCriticalCurrent

Links

Images

Classifications

Definitions

Landscapes

Abstract

The present invention provides a method and apparatus for selectively destroying dividing cells in living tissue formed of dividing cells and non-dividing cells. The dividing cells contain polarizable intracellular members and during late anaphase or telophase, the dividing cells are connected to one another by a cleavage furrow. According to the present method the living tissue is subjected to electric field conditions sufficient to cause movement of the polarizable intracellular members toward the cleavage furrow in response to a non-homogenous electric field being induced in the dividing cells. The non-homogenous electric field produces an increased density electric field in the region of the cleavage furrow. The movement of the polarizable intracellular members towards the cleavage furrow causes the break down thereof which results in destruction of the dividing cells, while the non-dividing cells of the living tissue remain intact.

Description

Claims (18)

What is claimed is:
1. A method for selectively destroying dividing cells in living tissue, the dividing cells having polarizable intracellular members, the method comprising the steps of:
subjecting the living tissue to a first electric field, wherein passage of the first electric field through the dividing cells in late anaphase or telophase transforms the field into a non-homogenous electric field, the non-homogenous electric field producing an increased density electric field in a region of a cleavage furrow, the non-homogenous electric field produced within the dividing cells being sufficient to create a condition within the dividing cells that increases the likelihood that the dividing cells are destroyed.
2. A method according toclaim 1, wherein the non-homogenous electric field is sufficient to move the polarizable intracellular members toward the cleavage furrow until the intracellular members disrupt the cleavage furrow causing destruction of the dividing cells, the cleavage furrow being in the form of a cytoplasm bridge membrane.
3. A method according toclaim 1, wherein the first electric field has a sufficient frequency so that the non-homogenous electric field produced in the dividing cells defines electric field lines which generally converge at a region of the cleavage furrow, thereby defining the increased density electric field.
4. A method according toclaim 1, wherein the step of subjecting the living tissue to the first electric field comprises the step of:
subjecting the living tissue to an alternating electric potential at a sufficient frequency to cause associated electric field lines to penetrate the dividing cells and form the non-homogenous electric field within the dividing cells.
5. A method according toclaim 1, wherein the step of transforming the first electric field into the non-homogenous electric field includes:
forming electric forces in the dividing cells which act to pull the polarizable intracellular members toward the increased density electric field region.
6. A method according toclaim 1, wherein the polarizable intracellular members are organelles.
7. A method according toclaim 1, wherein the step of subjecting the living tissue to the first electric field comprises the step of:
subjecting the living tissue to a pulsating alternating electric potential at a sufficient frequency to form the non-homogenous electric field within the dividing cells.
8. A method according toclaim 1, wherein the step of subjecting the living tissue to the first electric field comprises the step of:
subjecting the living tissue to an alternating electric potential at a frequency of about 200 kHz when the dividing cells are melanoma cells.
9. A method according toclaim 1, wherein the dividing cells comprise a first sub-cell and a second sub-cell with the cleavage furrow connecting the two in late anaphase or telophase.
10. A method according toclaim 1, wherein the step of subjecting the living tissue to the first electric field comprises the step of:
providing a first electrode;
providing a second electrode;
applying an alternating electric potential across the first and second electrodes, wherein the first and second electrodes are disposed in a vicinity of the living tissue to be treated.
11. A method according toclaim 2, wherein movement of the intracellular members toward the cleavage furrow increases pressure being exerted on the cleavage furrow, the increased pressure causing the region of the cleavage furrow to expand resulting in the cleavage furrow breaking apart and causing destruction of the dividing cells.
12. A method according toclaim 1, wherein the first electric field is a substantially uniform electric field.
13. A method for selectively destroying dividing cells in living tissue, the dividing cells containing polarizable intracellular members, the method comprising the step of:
subjecting the living tissue to first electric field conditions in late anaphase or telophase which is sufficient to cause displacement of the polarizable intracellular members towards a cleavage furrow connecting the dividing cells in response to a non-homogenous first electric field being induced in the dividing cells, the displacement of the polarizable intracellular members causing the break down of the cleavage furrow which results in the destruction of the dividing cells while non-dividing cells of the living tissue remain intact.
14. A method according toclaim 13, further including the steps of:
terminating the application of the first electric field; and
subsequently subjecting the living tissue to second electric field conditions which sufficient to cause displacement of the polarizable intracellular members towards the cleavage furrow in response to a non-homogenous second electric field being induced in the dividing cells, the non-homogenous second electric field being normal to the non-homogenous first electric field.
15. An apparatus for selectively destroying dividing cells in living tissue, the dividing cells having polarizable intracellular members, the system comprising:
a first electrode;
a second electrode, wherein the first and second electrodes are disposed in a vicinity of the living tissue to be treated; and
an electric field source for applying an alternating electric potential across the first and second electrodes, wherein passage of the electric field through dividing cells in late anaphase or telophase transforms the electric field into a non-homogenous electric field producing an increased density electric field in a region of a cleavage furrow, the non-homogenous electric field produced within the dividing cells being sufficient to move the polarizable intracellular members toward the cleavage furrow until the intracellular disrupt the cleavage furrow causing destruction of the dividing cells.
16. An apparatus according toclaim 15, wherein each of the first and second electrodes comprises an insulated electrode.
17. An apparatus according toclaim 15, wherein the alternating electric potential has a frequency of between about 10 kHz and about 1 MHz.
18. An apparatus according toclaim 15, wherein the electric field is a substantially uniform electric field prior to passing through the dividing cells.
US10/288,5622000-02-172002-11-05Method and apparatus for destroying dividing cellsExpired - LifetimeUS7016725B2 (en)

Priority Applications (14)

Application NumberPriority DateFiling DateTitle
US10/288,562US7016725B2 (en)2001-11-062002-11-05Method and apparatus for destroying dividing cells
US11/111,393US7599745B2 (en)2000-02-172005-04-21Treating a tumor or the like with an electric field
US11/111,236US7805201B2 (en)2000-02-172005-04-21Treating a tumor or the like with an electric field
US11/111,439US7565205B2 (en)2000-02-172005-04-21Treating a tumor or the like with electric fields at different orientations
US11/318,702US7565206B2 (en)2000-02-172005-12-27Treating a tumor or the like with electric fields at different orientations
US11/422,641US7599746B2 (en)2000-02-172006-06-07Apparatus and method for preventing the spread of cancerous metastases and for elimination of metastases
US12/146,918US8175698B2 (en)2000-02-172008-06-26Treating bacteria with electric fields
US12/190,886US7890183B2 (en)2000-02-172008-08-13Treating parasites with electric fields
US12/958,623US8447395B2 (en)2000-02-172010-12-02Treating bacteria with electric fields
US13/428,887US8447396B2 (en)2000-02-172012-03-23Treating bacteria with electric fields
US13/782,418US9039674B2 (en)2000-02-172013-03-01Treating bacteria with electric fields
US13/782,579US9056203B2 (en)2000-02-172013-03-01Treating bacteria with electric fields
US14/731,903US9440068B2 (en)2000-02-172015-06-05Treating bacteria with electric fields
US15/231,734US9750934B2 (en)2000-02-172016-08-08Treating bacteria with electric fields

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US33863201P2001-11-062001-11-06
US10/288,562US7016725B2 (en)2001-11-062002-11-05Method and apparatus for destroying dividing cells

Related Child Applications (5)

Application NumberTitlePriority DateFiling Date
PCT/IB2001/000202Continuation-In-PartWO2001060994A1 (en)2000-02-172001-02-16Method and apparatus for destroying dividing cells
US10204334Continuation-In-Part2001-02-16
US11/111,393Continuation-In-PartUS7599745B2 (en)2000-02-172005-04-21Treating a tumor or the like with an electric field
US11/111,439Continuation-In-PartUS7565205B2 (en)2000-02-172005-04-21Treating a tumor or the like with electric fields at different orientations
US11/111,236Continuation-In-PartUS7805201B2 (en)2000-02-172005-04-21Treating a tumor or the like with an electric field

Publications (2)

Publication NumberPublication Date
US20030097152A1true US20030097152A1 (en)2003-05-22
US7016725B2 US7016725B2 (en)2006-03-21

Family

ID=26965089

Family Applications (1)

Application NumberTitlePriority DateFiling Date
US10/288,562Expired - LifetimeUS7016725B2 (en)2000-02-172002-11-05Method and apparatus for destroying dividing cells

Country Status (1)

CountryLink
US (1)US7016725B2 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20040176804A1 (en)*2000-02-172004-09-09Yoram PaltiApparatus and method for optimizing tumor treatment efficiency by electric fields
US20050240228A1 (en)*2004-04-232005-10-27Yoram PaltiTreating a tumor or the like with electric fields at different frequencies
US20050240173A1 (en)*2002-10-022005-10-27Yoram PaltiTreating a tumor or the like with an electric field that is focused at a target region
WO2006085150A3 (en)*2004-12-272006-10-19Standen LtdTreating a tumor or the like with electric fields at different orientations
EP2345451A1 (en)2004-12-072011-07-20Standen Ltd.Electrodes for applying an electric field in-vivo over an extended period of time
US9833617B2 (en)2014-07-252017-12-05Loyalty Based Innovations, LLCApparatus and method for treating multiple tumors in patients with metastatic disease by electric fields
CN109475735A (en)*2016-04-042019-03-15诺沃医疗有限公司 Using Tumor Treatment Fields (TT Fields) to Reduce Cancer Cell Motility
WO2022003419A1 (en)*2020-06-302022-01-06Novocure GmbhFlexible transducer arrays with a polymer insulating layer for applying tumor treating fields (ttfields)
US11623084B2 (en)2014-07-252023-04-11Lifebridge Innovations, PbcApparatus and method for treating multiple tumors in patients with metastatic disease by electric fields

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US8175698B2 (en)2000-02-172012-05-08Novocure Ltd.Treating bacteria with electric fields
US7136699B2 (en)*2002-10-022006-11-14Standen, Ltd.Apparatus for destroying dividing cells
US8447395B2 (en)*2000-02-172013-05-21Novocure LtdTreating bacteria with electric fields
US7089054B2 (en)*2002-10-022006-08-08Standen Ltd.Apparatus and method for treating a tumor or the like
CN1416466A (en)2000-02-172003-05-07约朗姆·帕尔蒂 Method and apparatus for destroying dividing cells
WO2007024734A2 (en)*2005-08-192007-03-01Old Dominion Research FoundationUltrawideband antenna for operation in tissue
CN112402798B (en)2005-10-032021-11-16诺沃库勒有限责任公司Optimizing electric field characteristics to increase the effect of an electric field on proliferating cells
US8019414B2 (en)2006-04-052011-09-13Novocure Ltd.Treating cancer using electromagnetic fields in combination with other treatment regimens
EP2068739A4 (en)*2006-09-142013-01-23Lazure Technologies LlcDevice and method for destruction of cancer cells
ES2629612T3 (en)*2007-03-062017-08-11Novocure Ltd. Cancer treatment using electromagnetic fields in combination with photodynamic therapy
CN101820947A (en)*2007-08-142010-09-01诺沃库勒有限公司Use treating parasites with electric fields
US20090076500A1 (en)*2007-09-142009-03-19Lazure Technologies, LlcMulti-tine probe and treatment by activation of opposing tines
US8562602B2 (en)2007-09-142013-10-22Lazure Technologies, LlcMulti-layer electrode ablation probe and related methods
US20090076502A1 (en)*2007-09-142009-03-19Lazure Technologies, Llc.Prostate cancer ablation
US20100100093A1 (en)*2008-09-162010-04-22Lazure Technologies, Llc.System and method for controlled tissue heating for destruction of cancerous cells
US8728139B2 (en)2009-04-162014-05-20Lazure Technologies, LlcSystem and method for energy delivery to a tissue using an electrode array
US9526911B1 (en)2010-04-272016-12-27Lazure Scientific, Inc.Immune mediated cancer cell destruction, systems and methods
WO2013105987A2 (en)2011-02-152013-07-18Hemosonics, LlcCharacterization of blood hemostasis and oxygen transport parameters
US9655669B2 (en)2013-05-062017-05-23Novocure LimitedOptimizing treatment using TTFields by changing the frequency during the course of long term tumor treatment
US10779875B2 (en)2013-05-062020-09-22Novocure GmbhOptimizing treatment using TTfields by changing the frequency during the course of long term tumor treatment
US9725711B2 (en)*2014-03-102017-08-08Celleraser, LlcMethod and device for selective hyperthermic damage of target cells
US9726647B2 (en)2015-03-172017-08-08Hemosonics, LlcDetermining mechanical properties via ultrasound-induced resonance
US10188851B2 (en)2015-10-282019-01-29Novocure LimitedTTField treatment with optimization of electrode positions on the head based on MRI-based conductivity measurements
EP4454697A3 (en)2016-06-302024-12-25Novocure GmbHArrays for longitudinal delivery of ttfields to a body
CA3049949C (en)2017-01-192024-04-23Novocure LimitedSystem for viewing cell cultures under a microscope whilst applying tumor treating fields
US10953209B2 (en)2018-03-282021-03-23Board Of Regents Of The University Of Texas SystemTreating tumors using TTFields combined with a PARP inhibitor
CN112566665A (en)2018-04-092021-03-26莫舍·吉拉迪Treatment of tumors with TTfields and Aurora kinase inhibitors
CN112424626B (en)2018-04-102025-07-08诺沃库勒有限责任公司Method for optimizing a plurality of electrode positions and creating a 3D model
MX2020012673A (en)2018-07-032021-04-28Edwin chang USE OF ALTERNATIVE ELECTRICAL FIELDS TO INCREASE THE PERMEABILITY OF THE CELL MEMBRANE.
US11179322B2 (en)2018-07-102021-11-23Novocure GmbhMethods and compositions for treating tumors with TTFields and sorafenib
BR112020025692A2 (en)2018-07-102021-03-16Novocure Gmbh INHIBITION OF VIRAL INFECTION USING ALTERNATE ELECTRIC FIELDS
KR102607603B1 (en)2018-07-182023-11-29노보큐어 게엠베하 Use of power loss density and related measurements to quantify tumor treatment field capacity
CN113908433A (en)2018-08-232022-01-11诺沃库勒有限责任公司 Using alternating electric fields to improve the permeability of the blood-brain barrier
US11160977B2 (en)2018-09-042021-11-02Novocure GmbhDelivering tumor treating fields (TTFields) to the infratentorial brain
CN112770806A (en)2018-09-072021-05-07诺沃库勒有限责任公司Treatment of autoimmune diseases using alternating electric fields to reduce proliferation of T cells
US11986647B2 (en)2018-09-072024-05-21Novocure GmbhTreating autoinflammatory and mitochondrial diseases using an alternating electric field
EP3984590B1 (en)2018-10-152022-12-07Novocure GmbHGenerating tumor treating fields (ttfields) with high uniformity throughout the brain
CN112955208B (en)2018-10-252024-11-22诺沃库勒有限责任公司 Methods of delivering alternating electric fields (eg, TTFIELDS) to the spinal anatomy of a subject
WO2020102312A1 (en)2018-11-132020-05-22The Methodist HospitalMethod and apparatus for oncomagnetic treatement
CN113015553B (en)2018-11-192025-01-14诺沃库勒有限责任公司 Arrays for delivering tumor treating fields (TTFields) with selectively addressable subelements
MX2021002625A (en)2018-11-292021-05-12Novocure GmbhEnhanced-flexibility transducer arrays for delivering ttfields (tumor treating fields).
US11276171B2 (en)2019-01-082022-03-15Novocure GmbhEvaluating quality of segmentation of an image into different types of tissue for planning treatment using tumor treating fields (TTFields)
CN113692302A (en)2019-02-072021-11-23V·K·沙玛System and method for treating cancer cells with alternating polarity magnetic fields
US11344740B2 (en)2019-02-072022-05-31Asha Medical, Inc.System and methods for treating cancer cells with alternating polarity magnetic fields
US11027143B2 (en)2020-02-062021-06-08Vivek K. SharmaSystem and methods for treating cancer cells with alternating polarity magnetic fields
WO2020174403A1 (en)2019-02-262020-09-03Moshe GiladiDetermining a frequency for ttfields treatment based on an electrical characteristic of targeted cancer cells
EP3954314B1 (en)2019-02-272025-01-08Novocure GmbHDelivering tumor treating fields (ttfields) using implantable transducer arrays
US11911610B2 (en)2019-03-292024-02-27Novocure GmbhMethods for restoring sensitivity to TTFields in TTFields-resistant cancer cells with PTGER3 inhibitors
CN113966243A (en)2019-04-172022-01-21诺沃库勒有限责任公司Uploading data from an isolated system without compromising isolation
CN114364432A (en)2019-07-312022-04-15诺沃库勒有限责任公司Applying a tumor treatment field (TTfield) via electrodes embedded in a cranial implant
WO2021024170A1 (en)2019-08-052021-02-11Voloshin Sela TaliIncreasing cancer cells' sensitivity to tumor treating fields (ttfields) by inhibiting il11 activity
EP4021559B1 (en)2019-08-302023-10-25Novocure GmbHDelivering tumor treating fields (ttfields) to the neck
WO2021064036A1 (en)2019-09-302021-04-08Tdk Electronics AgPolycrystalline ceramic solid, dielectric electrode comprising the solid, device comprising the electrode and method of production
US11534601B2 (en)2019-11-082022-12-27Novocure GmbhPerforated hydrogel configurations and methods of production and use thereof
JP7670721B6 (en)2019-12-312025-06-06ノボキュア ゲーエムベーハー High-voltage, highly efficient sine wave generator that prevents spikes during amplitude adjustment and channel switching
HUE061733T2 (en)2019-12-312023-08-28Novocure GmbhArrays for delivering tumor treating fields (ttfields) with individually accessible electrode elements and temperature sensors
US12121739B2 (en)2019-12-312024-10-22Novocure GmbhMethods, systems, and apparatuses for managing temperatures induced by alternating fields
TWI864225B (en)2020-01-222024-12-01瑞士商諾沃庫勒有限責任公司Assemblies and transducer arrays for a ttfield-generating system
WO2021198864A1 (en)2020-03-302021-10-07Novocure GmbhIntravenous / intra-spinal / intra-cavity / intraventricular delivery of ttfields (tumor treating fields) for treating cancer and metastases
JP2023522817A (en)2020-04-242023-06-01ノボキュア ゲーエムベーハー Use of alternating electric fields to increase the permeability of the blood-brain barrier
TWI889816B (en)2020-05-062025-07-11瑞士商諾沃庫勒有限責任公司Conductive pad generating tumor treating field and methods of production and use thereof
WO2021257967A1 (en)2020-06-192021-12-23The Methodist Hospital Dba Houston Methodist HospitalMethod and apparatus for oncomagnetic treatment
US11818943B2 (en)2020-06-252023-11-14Novocure GmbhFabricating organic light emitting diodes (OLEDs) using tubulin
WO2022003519A2 (en)2020-06-292022-01-06Novocure GmbhTreating autoinflammatory and mitochondrial diseases using an alternating electric field
EP4213933A1 (en)2020-09-182023-07-26Novocure GmbhMethods and compositions for treating coronavirus
US12114991B2 (en)2020-09-252024-10-15Novocure GmbhVarying the metallization area on individual electrode elements in a tumor treating fields (TTFields) system to maximize current without overheating
DE102020133165B9 (en)2020-12-112024-06-06Tdk Electronics Ag Ceramic electrode, assembly with the ceramic electrode, arrangement with the ceramic electrode and method for producing a ceramic electrode
US11883652B2 (en)2020-12-212024-01-30Novocure GmbhOptimization of composite electrode
CN116615268A (en)2020-12-242023-08-18诺沃库勒有限责任公司 Methods and compositions for using alternating electric fields in gene therapy
US12397151B2 (en)2021-02-172025-08-26Novocure GmbhArrays for delivering tumor treating fields (TTFields) with sets of electrode elements having individually adjustable active areas
EP4480527A3 (en)2021-03-122025-03-12Novocure GmbHMethods of production of an electrode array
EP4271466A2 (en)2021-03-182023-11-08Novocure GmbhConstructing a 3d phantom with liquid hydrogel
CN117120139A (en)2021-03-312023-11-24诺沃库勒有限责任公司Impedance tomography using electrodes of Tumor Treatment Field (TTFIELD) system
JP2024524745A (en)2021-07-212024-07-05ノボキュア ゲーエムベーハー Conductive pads for generating tumor treatment fields and methods of making and using same - Patents.com
WO2023042080A1 (en)2021-09-142023-03-23Novocure GmbhTemperature independent method and system for applying ttfields
EP4376937A1 (en)2021-09-302024-06-05Novocure GmbHMethod and system for applying tumor treating fields interfacing with hair follicles
WO2023095111A1 (en)2021-11-292023-06-01Novocure GmbhMethods of reducing ciliogenesis with alternating electric fields
US20230173288A1 (en)2021-12-072023-06-08Novocure GmbhCompact dc system for delivering a square wave ac signal
US20230173265A1 (en)2021-12-102023-06-08Novocure GmbhGarment providing a biasing force on a transducer array
US12434051B2 (en)2021-12-102025-10-07Novocure GmbhCompression garment assembly for applying TTFields and methods of production and use thereof
MX2024006037A (en)2021-12-102024-06-05Novocure GmbhCompression garment assembly for applying ttfields and methods of production and use thereof.
CN118591405A (en)2021-12-302024-09-03诺沃库勒有限责任公司 Selecting treatment parameter values using tumor treating fields (TTFIELDS)
WO2023187689A1 (en)2022-03-302023-10-05Novocure GmbhUsing interleaved cooling periods to increase the peak intensity of tumor treating fields
WO2023193012A2 (en)2022-04-012023-10-05The Board Of Regents Of The University Of Texas SystemMethods and apparatus for applying tumor treating fields combined with personalized ultra-fractionated stereotactic adaptive radiotherapy
WO2023242741A1 (en)2022-06-132023-12-21Novocure GmbhSystems and methods for increasing intestinal absorption of therapeutic agents
EP4539924A1 (en)2022-06-202025-04-23Novocure GmbHCompositions, systems, and methods for treating cancer using tumor treating fields and vegf inhibitors
US20230407282A1 (en)2022-06-212023-12-21Novocure GmbhSystems and methods for treating conditions and diseases using alternating electric fields and crispr-cas system
US20240081939A1 (en)2022-09-082024-03-14Novocure GmbhConstructing a 3d phantom with a matrix material having conductive particles dispersed therein
WO2024069488A1 (en)2022-09-272024-04-04Novocure GmbhIngestible implantable device to measure internal ttfield intensity
CA3180284A1 (en)2022-09-292024-03-29Novocure GmbhTransducer array having a temperature sensor isolation layer between a temperature sensor and external environment
EP4561681A1 (en)2022-09-292025-06-04Novocure GmbhSystem and method for maintaining ttfields during battery changes
EP4593870A1 (en)2022-09-302025-08-06Novocure GmbHCompositions, systems, and methods for treating cancer using alternating electric fields and apoptotic cancer cell vaccination
EP4554658A1 (en)2022-09-302025-05-21Novocure GmbhSingle wire temperature measurement solution for a ttfield application system and methods of production and use thereof
US20240110174A1 (en)2022-09-302024-04-04Novocure GmbhCompositions, systems, and methods for treating cancer using alternating electric fields and dendritic cells
US20240108699A1 (en)2022-09-302024-04-04Novocure GmbhCompositions, systems, and methods for reducing electrosensation and/or skin irritation
KR20250114365A (en)2022-11-302025-07-29노보큐어 게엠베하 Transducer array with alternative array material
WO2024127192A1 (en)2022-12-132024-06-20Novocure GmbhWireless transducer arrays applying tumor treating fields and systems and methods of use thereof
WO2024141995A1 (en)2022-12-282024-07-04Novocure GmbhCompositions, systems, and methods for treating cancer using tumor treating fields and anti-vegfr-2 antibodies
US12268863B2 (en)2023-02-062025-04-08Novocure GmbhShiftable transducer array with anisotropic material layer
US20240325532A1 (en)2023-03-302024-10-03Novocure GmbhCompositions, systems, and methods for treating cancer using tumor treating fields and chimeric antigen receptor (car)-immune cells
WO2024201385A1 (en)2023-03-302024-10-03Novocure GmbhCompositions, systems, and methods for treating cancer using tumor treating fields and killer cells
US20240399141A1 (en)2023-03-312024-12-05Novocure GmbhMicroneedles to overcome contact resistance
US20240415869A1 (en)2023-06-152024-12-19Novocure GmbhCompositions, systems, and methods for treating cancer using tumor treating fields (ttfields) and thioredoxin/glutathione inhibitors
WO2025062369A1 (en)2023-09-212025-03-27Novocure GmbhCompositions, systems, and methods for treating cancer using tumor treating fields with immune checkpoint inhibitors and mhc class i activators
US20250108203A1 (en)2023-09-282025-04-03Novocure GmbhTransducer array having subarrays and methods of production and use thereof
WO2025068877A1 (en)2023-09-292025-04-03Novocure GmbhLow frequency rf ablation system
WO2025068918A1 (en)2023-09-292025-04-03Novocure GmbhApparatus and method of reapplying transducer arrays to a patient
US20250135196A1 (en)2023-10-272025-05-01Brown UniversityCompositions, systems, and methods for treating cancer using tumor treating fields with inhibitors of mif, mica, and/or micb
WO2025186743A1 (en)2024-03-052025-09-12Novocure GmbhCombinations for treating cancer in standard of care and/or profibrotic chemotherapeutic agent-naive patients using tumor treating fields and chemotherapeutic agents
WO2025191539A1 (en)2024-03-152025-09-18Novocure GmbhReduced impedance transducer array for applying alternating electric fields and methods of production and use thereof

Citations (40)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US2220269A (en)*1934-03-201940-11-05Firm Siemens Reiniger Werke AgElectrode means
US4016886A (en)*1974-11-261977-04-12The United States Of America As Represented By The United States Energy Research And Development AdministrationMethod for localizing heating in tumor tissue
US4121592A (en)*1975-08-041978-10-24Critical Systems, Inc.Apparatus for heating tissue
US4263920A (en)*1978-03-251981-04-28Manfred TastoMethod of and device for determining internal body structure
US4467809A (en)*1982-09-171984-08-28Biolectron, Inc.Method for non-invasive electrical stimulation of epiphyseal plate growth
US4472506A (en)*1981-01-131984-09-18Liburdy Robert PMethod for determining cell membrane dielectric breakdown
US4622952A (en)*1983-01-131986-11-18Gordon Robert TCancer treatment method
US4626506A (en)*1983-06-291986-12-02Kernforschungsanlage JulichProcess and device for the determination of cells secreting cellular contents
US4676258A (en)*1983-01-241987-06-30Kureha Kagaku Kogyo Kabushiki KaishaDevice for hyperthermia
US4822470A (en)*1987-10-091989-04-18Baylor College Of MedicineMethod of and apparatus for cell poration and cell fusion using radiofrequency electrical pulses
US4846178A (en)*1986-06-051989-07-11Beijing Information Technology InstituteElectric field therapeutic apparatus
US4846196A (en)*1986-01-291989-07-11Wiksell Hans O TMethod and device for the hyperthermic treatment of tumors
US4923814A (en)*1986-05-091990-05-08Electropore, Inc.High speed, high power apparatus for vesicle prealignment, poration, loading and fusion in uniform electric fields and method therefor
US4936303A (en)*1987-11-201990-06-26UltrathermicsUltrasonic heating apparatus and method
US4971991A (en)*1987-12-011990-11-20Kohshiro UmemuraPhysiological function enhancing agents activated by ultrasonic waves for the treatment of tumors
US5099756A (en)*1989-06-011992-03-31Harry H. LeveenRadio frequency thermotherapy
US5158071A (en)*1988-07-011992-10-27Hitachi, Ltd.Ultrasonic apparatus for therapeutical use
US5236410A (en)*1990-08-021993-08-17Ferrotherm International, Inc.Tumor treatment method
US5312813A (en)*1991-05-031994-05-17University Technologies InternationalBiofilm reduction method
US5386837A (en)*1993-02-011995-02-07Mmtc, Inc.Method for enhancing delivery of chemotherapy employing high-frequency force fields
US5389069A (en)*1988-01-211995-02-14Massachusetts Institute Of TechnologyMethod and apparatus for in vivo electroporation of remote cells and tissue
US5441746A (en)*1989-12-221995-08-15Molecular Bioquest, Inc.Electromagnetic wave absorbing, surface modified magnetic particles for use in medical applications, and their method of production
US5441532A (en)*1991-06-261995-08-15Massachusetts Institute Of TechnologyAdaptive focusing and nulling hyperthermia annular and monopole phased array applicators
US5468223A (en)*1992-11-301995-11-21C.N.R.S. ParisElectrochemotherapy
US5606971A (en)*1995-11-131997-03-04Artann Corporation, A Nj Corp.Method and device for shear wave elasticity imaging
US5674267A (en)*1993-03-301997-10-07Centre National De La Recherche ScientifiqueElectric pulse applicator using pairs of needle electrodes for the treatment of biological tissue
US5807257A (en)*1994-07-011998-09-15Interstitial, Inc.Breast cancer detection, imaging and screening by electromagnetic millimeter waves
US5964726A (en)*1994-02-251999-10-12Ramot University Authority For Applied Research And Industrial DevelopmentApparatus and method for efficient incorporation of molecules into cells
US5976092A (en)*1998-06-151999-11-02Chinn; Douglas O.Combination stereotactic surgical guide and ultrasonic probe
US5984882A (en)*1996-08-191999-11-16Angiosonics Inc.Methods for prevention and treatment of cancer and other proliferative diseases with ultrasonic energy
US6027488A (en)*1998-06-032000-02-22Genetronics, Inc.Flow-through electroporation system for ex vivo gene therapy
US6043066A (en)*1997-09-042000-03-28Mangano; Joseph A.Cell separation using electric fields
US6055453A (en)*1997-08-012000-04-25Genetronics, Inc.Apparatus for addressing needle array electrodes for electroporation therapy
US6096020A (en)*1996-09-092000-08-01Genetronics, Inc.Electroporation employing user-configured pulsing scheme
US6319901B1 (en)*1998-10-152001-11-20Ichor Medical Systems, Inc.Methods for prolonging cell membrane permeability
US6413255B1 (en)*1999-03-092002-07-02Thermage, Inc.Apparatus and method for treatment of tissue
US6447499B2 (en)*1995-07-282002-09-10James R. GrayUse of a polarized field to modify the efficacy of a bioactive agent
US20020193833A1 (en)*1999-03-252002-12-19Genetronics, Inc.Method and apparatus for reducing electroporation-mediated muscle reaction and pain response
US20030060856A1 (en)*2001-08-132003-03-27Victor ChornenkyApparatus and method for treatment of benign prostatic hyperplasia
US6856839B2 (en)*2000-02-022005-02-15Catholic University Of AmericaUse of electromagnetic fields in cancer and other therapies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
BE794566A (en)1972-01-281973-07-26Esb Inc BIOELECTROCHEMICAL REGENERATOR AND STIMULATOR AND IN VIVO APPLICATION METHODS OF ELECTRIC ENERGY TO CELLS AND TISSUES.
JPS5547870A (en)1978-02-241980-04-05Lawrence Joseph LMedical treatment method
GB2043453A (en)1979-02-221980-10-08Electrochem Tech CorpImprovements in or relating to an electrode
FR2627987B3 (en)1988-03-041990-02-02Indiba Sa ELECTRONIC APPARATUS FOR MEDICAL AND COSMETIC THERAPY
US5718246A (en)*1996-01-031998-02-17Preferential, Inc.Preferential induction of electrically mediated cell death from applied pulses
US6366808B1 (en)*2000-03-132002-04-02Edward A. SchroeppelImplantable device and method for the electrical treatment of cancer
CN1416466A (en)2000-02-172003-05-07约朗姆·帕尔蒂 Method and apparatus for destroying dividing cells

Patent Citations (42)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US2220269A (en)*1934-03-201940-11-05Firm Siemens Reiniger Werke AgElectrode means
US4016886A (en)*1974-11-261977-04-12The United States Of America As Represented By The United States Energy Research And Development AdministrationMethod for localizing heating in tumor tissue
US4121592A (en)*1975-08-041978-10-24Critical Systems, Inc.Apparatus for heating tissue
US4263920A (en)*1978-03-251981-04-28Manfred TastoMethod of and device for determining internal body structure
US4472506A (en)*1981-01-131984-09-18Liburdy Robert PMethod for determining cell membrane dielectric breakdown
US4467809A (en)*1982-09-171984-08-28Biolectron, Inc.Method for non-invasive electrical stimulation of epiphyseal plate growth
US4622952A (en)*1983-01-131986-11-18Gordon Robert TCancer treatment method
US4676258A (en)*1983-01-241987-06-30Kureha Kagaku Kogyo Kabushiki KaishaDevice for hyperthermia
US4626506A (en)*1983-06-291986-12-02Kernforschungsanlage JulichProcess and device for the determination of cells secreting cellular contents
US4846196A (en)*1986-01-291989-07-11Wiksell Hans O TMethod and device for the hyperthermic treatment of tumors
US4923814A (en)*1986-05-091990-05-08Electropore, Inc.High speed, high power apparatus for vesicle prealignment, poration, loading and fusion in uniform electric fields and method therefor
US4846178A (en)*1986-06-051989-07-11Beijing Information Technology InstituteElectric field therapeutic apparatus
US4822470A (en)*1987-10-091989-04-18Baylor College Of MedicineMethod of and apparatus for cell poration and cell fusion using radiofrequency electrical pulses
US4936303A (en)*1987-11-201990-06-26UltrathermicsUltrasonic heating apparatus and method
US4971991A (en)*1987-12-011990-11-20Kohshiro UmemuraPhysiological function enhancing agents activated by ultrasonic waves for the treatment of tumors
US5389069A (en)*1988-01-211995-02-14Massachusetts Institute Of TechnologyMethod and apparatus for in vivo electroporation of remote cells and tissue
US5158071A (en)*1988-07-011992-10-27Hitachi, Ltd.Ultrasonic apparatus for therapeutical use
US5099756A (en)*1989-06-011992-03-31Harry H. LeveenRadio frequency thermotherapy
US5441746A (en)*1989-12-221995-08-15Molecular Bioquest, Inc.Electromagnetic wave absorbing, surface modified magnetic particles for use in medical applications, and their method of production
US5236410A (en)*1990-08-021993-08-17Ferrotherm International, Inc.Tumor treatment method
US5312813A (en)*1991-05-031994-05-17University Technologies InternationalBiofilm reduction method
US5441532A (en)*1991-06-261995-08-15Massachusetts Institute Of TechnologyAdaptive focusing and nulling hyperthermia annular and monopole phased array applicators
US5468223A (en)*1992-11-301995-11-21C.N.R.S. ParisElectrochemotherapy
US5386837A (en)*1993-02-011995-02-07Mmtc, Inc.Method for enhancing delivery of chemotherapy employing high-frequency force fields
US5674267A (en)*1993-03-301997-10-07Centre National De La Recherche ScientifiqueElectric pulse applicator using pairs of needle electrodes for the treatment of biological tissue
US5964726A (en)*1994-02-251999-10-12Ramot University Authority For Applied Research And Industrial DevelopmentApparatus and method for efficient incorporation of molecules into cells
US5807257A (en)*1994-07-011998-09-15Interstitial, Inc.Breast cancer detection, imaging and screening by electromagnetic millimeter waves
US20020193832A1 (en)*1995-07-282002-12-19James GrayUse of a polarizing field to modify the efficacy of a bioactive agent
US6447499B2 (en)*1995-07-282002-09-10James R. GrayUse of a polarized field to modify the efficacy of a bioactive agent
US5606971A (en)*1995-11-131997-03-04Artann Corporation, A Nj Corp.Method and device for shear wave elasticity imaging
US5984882A (en)*1996-08-191999-11-16Angiosonics Inc.Methods for prevention and treatment of cancer and other proliferative diseases with ultrasonic energy
US6096020A (en)*1996-09-092000-08-01Genetronics, Inc.Electroporation employing user-configured pulsing scheme
US6055453A (en)*1997-08-012000-04-25Genetronics, Inc.Apparatus for addressing needle array electrodes for electroporation therapy
US6068650A (en)*1997-08-012000-05-30Gentronics Inc.Method of Selectively applying needle array configurations
US6043066A (en)*1997-09-042000-03-28Mangano; Joseph A.Cell separation using electric fields
US6027488A (en)*1998-06-032000-02-22Genetronics, Inc.Flow-through electroporation system for ex vivo gene therapy
US5976092A (en)*1998-06-151999-11-02Chinn; Douglas O.Combination stereotactic surgical guide and ultrasonic probe
US6319901B1 (en)*1998-10-152001-11-20Ichor Medical Systems, Inc.Methods for prolonging cell membrane permeability
US6413255B1 (en)*1999-03-092002-07-02Thermage, Inc.Apparatus and method for treatment of tissue
US20020193833A1 (en)*1999-03-252002-12-19Genetronics, Inc.Method and apparatus for reducing electroporation-mediated muscle reaction and pain response
US6856839B2 (en)*2000-02-022005-02-15Catholic University Of AmericaUse of electromagnetic fields in cancer and other therapies
US20030060856A1 (en)*2001-08-132003-03-27Victor ChornenkyApparatus and method for treatment of benign prostatic hyperplasia

Cited By (21)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US7146210B2 (en)2000-02-172006-12-05Standen Ltd.Apparatus and method for optimizing tumor treatment efficiency by electric fields
US20040176804A1 (en)*2000-02-172004-09-09Yoram PaltiApparatus and method for optimizing tumor treatment efficiency by electric fields
US20050240173A1 (en)*2002-10-022005-10-27Yoram PaltiTreating a tumor or the like with an electric field that is focused at a target region
US7706890B2 (en)2002-10-022010-04-27Standen LtdTreating a tumor or the like with an electric field that is focused at a target region
US20050240228A1 (en)*2004-04-232005-10-27Yoram PaltiTreating a tumor or the like with electric fields at different frequencies
US8244345B2 (en)*2004-04-232012-08-14Novocure LtdTreating a tumor or the like with electric fields at different frequencies
EP2345451A1 (en)2004-12-072011-07-20Standen Ltd.Electrodes for applying an electric field in-vivo over an extended period of time
EP2364747A1 (en)2004-12-072011-09-14Standen Ltd.Electrodes for applying an electric field in-vivo over an extended period of time
EP2364748A1 (en)2004-12-072011-09-14Standen Ltd.Electrodes for applying an electric field in-vivo over an extended period of time
EP3666328A1 (en)*2004-12-272020-06-17Novocure LimitedTreating a tumor or the like with electric fields at different orientations
WO2006085150A3 (en)*2004-12-272006-10-19Standen LtdTreating a tumor or the like with electric fields at different orientations
US9833617B2 (en)2014-07-252017-12-05Loyalty Based Innovations, LLCApparatus and method for treating multiple tumors in patients with metastatic disease by electric fields
US10675460B2 (en)2014-07-252020-06-09Loyalty Based Innovations, LLCApparatus and method for treating multiple tumors in patients with metastatic disease by electric fields
US11623084B2 (en)2014-07-252023-04-11Lifebridge Innovations, PbcApparatus and method for treating multiple tumors in patients with metastatic disease by electric fields
US11957904B2 (en)2014-07-252024-04-16Lifebridge Innovations, PbcApparatus and method for treating multiple tumors in patients with metastatic disease by electric fields
US12064624B2 (en)2014-07-252024-08-20Lifebridge Innovations, PbcApparatus and method for treating multiple tumors in patients with metastatic disease by electric fields
CN109475735A (en)*2016-04-042019-03-15诺沃医疗有限公司 Using Tumor Treatment Fields (TT Fields) to Reduce Cancer Cell Motility
WO2022003419A1 (en)*2020-06-302022-01-06Novocure GmbhFlexible transducer arrays with a polymer insulating layer for applying tumor treating fields (ttfields)
JP2023508763A (en)*2020-06-302023-03-03ノボキュア ゲーエムベーハー A flexible transducer array with a polymer insulating layer for applying tumor therapeutic electric fields (TT fields)
JP7498290B2 (en)2020-06-302024-06-11ノボキュア ゲーエムベーハー FLEXIBLE TRANSDUCER ARRAY WITH POLYMER INSULATING LAYER FOR APPLYING TUMOR TREATMENT ELECTRIC FIELDS (TT FIELDS) - Patent application
EP4567054A3 (en)*2020-06-302025-06-25Novocure GmbHFlexible transducer arrays with a polymer insulating layer for applying tumor treating fields (ttfields)

Also Published As

Publication numberPublication date
US7016725B2 (en)2006-03-21

Similar Documents

PublicationPublication DateTitle
US7016725B2 (en)Method and apparatus for destroying dividing cells
US7333852B2 (en)Method and apparatus for destroying dividing cells
JP2004505604A5 (en)
US7565205B2 (en)Treating a tumor or the like with electric fields at different orientations
US7519420B2 (en)Apparatus for selectively destroying dividing cells
EP2183024B1 (en)Treating parasites with electric fields
US8175698B2 (en)Treating bacteria with electric fields
US7565206B2 (en)Treating a tumor or the like with electric fields at different orientations
HK1139089B (en)Treating parasites with electric fields
HK1139089A (en)Treating parasites with electric fields

Legal Events

DateCodeTitleDescription
ASAssignment

Owner name:STANDEN LTD., CHANNEL ISLANDS

Free format text:ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PALTI, YORAM;REEL/FRAME:013711/0669

Effective date:20021118

STCFInformation on status: patent grant

Free format text:PATENTED CASE

FEPPFee payment procedure

Free format text:PAT HOLDER NO LONGER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: STOL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FEPPFee payment procedure

Free format text:PAT HOLDER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: LTOS); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAYFee payment

Year of fee payment:4

ASAssignment

Owner name:NOVOCURE LIMITED

Free format text:CHANGE OF NAME;ASSIGNOR:STANDEN LIMITED;REEL/FRAME:026311/0210

Effective date:20110221

ASAssignment

Owner name:DEUTSCHE BANK TRUST COMPANY AMERICAS, NEW YORK

Free format text:SECURITY AGREEMENT;ASSIGNOR:NOVOCURE LIMITED;REEL/FRAME:029845/0135

Effective date:20130128

FPAYFee payment

Year of fee payment:8

ASAssignment

Owner name:NOVOCURE LIMITED, JERSEY

Free format text:RELEASE OF SECURITY INTEREST;ASSIGNOR:DEUTSCHE BANK TRUST COMPANY AMERICAS;REEL/FRAME:031866/0567

Effective date:20131220

ASAssignment

Owner name:BIOPHARMA SECURED INVESTMENTS III HOLDINGS CAYMAN

Free format text:SECURITY INTEREST;ASSIGNOR:NOVOCURE LIMITED;REEL/FRAME:034866/0402

Effective date:20150130

MAFPMaintenance fee payment

Free format text:PAYMENT OF MAINTENANCE FEE, 12TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2553)

Year of fee payment:12

ASAssignment

Owner name:NOVOCURE LIMITED, JERSEY

Free format text:RELEASE BY SECURED PARTY;ASSIGNOR:BIOPHARMA SECURED INVESTMENTS III HOLDINGS CAYMAN LP;REEL/FRAME:044858/0416

Effective date:20180207

Owner name:BIOPHARMA CREDIT PLC, UNITED KINGDOM

Free format text:SECURITY INTEREST;ASSIGNOR:NOVOCURE LIMITED;REEL/FRAME:045278/0825

Effective date:20180207

Owner name:BIOPHARMA CREDIT PLC, UNITED KINGDOM

Free format text:SECURITY INTEREST;ASSIGNOR:NOVOCURE LIMITED;REEL/FRAME:045284/0851

Effective date:20180207

ASAssignment

Owner name:BIOPHARMA CREDIT PLC, UNITED KINGDOM

Free format text:SECURITY INTEREST;ASSIGNOR:NOVOCURE GMBH;REEL/FRAME:050395/0398

Effective date:20190424

FEPPFee payment procedure

Free format text:ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

ASAssignment

Owner name:NOVOCURE GMBH, SWITZERLAND

Free format text:ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVOCURE LIMITED;REEL/FRAME:050110/0098

Effective date:20190424

ASAssignment

Owner name:NOVOCURE LIMITED, JERSEY

Free format text:RELEASE BY SECURED PARTY;ASSIGNOR:BIOPHARMA CREDIT PLC;REEL/FRAME:052383/0705

Effective date:20190424

ASAssignment

Owner name:NOVOCURE LIMITED, JERSEY

Free format text:RELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 045278/0825;ASSIGNOR:BIOPHARMA CREDIT PLC;REEL/FRAME:052391/0549

Effective date:20190424

ASAssignment

Owner name:BPCR LIMITED PARTNERSHIP, UNITED KINGDOM

Free format text:OMNIBUS CONFIRMATION OF ASSIGNMENT AGREEMENT;ASSIGNOR:BIOPHARMA CREDIT PLC;REEL/FRAME:052741/0173

Effective date:20200521

ASAssignment

Owner name:NOVOCURE GMBH, SWITZERLAND

Free format text:RELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 50395/0398;ASSIGNOR:BPCR LIMITED PARTNERSHIP;REEL/FRAME:053538/0623

Effective date:20200818

ASAssignment

Owner name:NOVOCURE LIMITED, JERSEY

Free format text:RELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 45278 0825;ASSIGNOR:BIOPHARMA CREDIT PLC;REEL/FRAME:053597/0335

Effective date:20200818

ASAssignment

Owner name:JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT, ILLINOIS

Free format text:SECURITY INTEREST;ASSIGNOR:NOVOCURE GMBH;REEL/FRAME:054344/0510

Effective date:20201106

ASAssignment

Owner name:NOVOCURE GMBH, SWITZERLAND

Free format text:RELEASE BY SECURED PARTY;ASSIGNOR:JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT;REEL/FRAME:067211/0839

Effective date:20240423

ASAssignment

Owner name:BIOPHARMA CREDIT PLC, UNITED KINGDOM

Free format text:PATENT SECURITY AGREEMENT;ASSIGNOR:NOVOCURE GMBH (SWITZERLAND);REEL/FRAME:067315/0399

Effective date:20240501


[8]ページ先頭

©2009-2025 Movatter.jp